Italfarmaco SpA products

Dedralen (doxazosina) is an alpha-blocker antihypertensive drug well-established medication in combined treatments requiring an alpha-blocking activity with positive effects, also from the metabolic standpoint.

Vasexten (barnidipina) third-generation dihydropyridine calcium channel antagonist holds high efficacy standards, improving the tolerability profile, minimizing the typical side effects of this class (peripheral edemas and reflex tachycardia) thanks to its lipophilic structure and formulation in modified-release capsules (unique for its class). Vasexten allows optimal control of the hypertensive patient both as single-agent therapy and in combination with other antihypertensive drugs. On Vasexten Italfarmaco has obtained different and original experimental data about blood pressure control, organ protection in collaboration with head physicians and primary Italian Specialist Centers.

Coripren is the pre-established combination of Enalapril and Lercanidipine. Coripren uses the synergy between ace-inhibitor and calcium channel antagonist in accordance with the most recent European Guidelines. Besides the superior blood pressure control provided in terms of responders rate, the reduced number of tablets obtained with the combination is a pivotal factor to achieve full treatment adherence, thus maintaining the therapeutic goal.

Xarenel provides Vitamin D, when required, in the prevention and treatment of deficiencies. Different formulations, flexible dosing options and a good tolerability profile enable to provide a different treatment option, designed according to the single patient requirements. There are increasing scientific evidence and publications supporting benefit treatments resulting from maintaining optimal vitamin D levels both in patients with bone metabolis disorders and patients with major cardiovascular, neurologic and immune diseases.

Natemille in orodispersible tablets with 600 mg and 1,000 IU of Vitamin D3, provides the daily intake of Vitamin D recommended by the major guidelines and the amount of calcium sufficient for patients already taking a certain amount of dietary calcium.